What VCs really think of the market right now with MPM Capital, Endeavor Venture Fund and Two Bear Capital
14 Dec 2023
22m
BioSpace · Business
BioSpace
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Episodes
Major FDA approvals for Vertex/CRISPR; bluebird gets black box warning and price scrutiny
13 Dec 2023
16m
Fast and furious evolution: How to ensure AI is catalyst for positive societal change with Microsoft and IQVIA
12 Dec 2023
31m
Integrating AI in life sciences to change employee behavior with Microsoft and IQVIA
07 Dec 2023
20m
GLP-1 and ADC rollercoasters pick up speed
06 Dec 2023
13m
Artificial Intelligence, Part 3: Improving Communication to Impact Patient Behavior
05 Dec 2023
17m
Artificial Intelligence, Part 2: Human Interaction, Liability, and Patient Safety
30 Nov 2023
16m
Deals, Dupixent and GLP-1 drug shortages
29 Nov 2023
17m
First ever CRISPR gene therapy approval: What happens next?
21 Nov 2023
13m
Artificial Intelligence, Part 1: Bias, Access, ROI, Potential Success and Failure
16 Nov 2023
18m
Zepbound vs Wegovy: A two horse race
15 Nov 2023
14m
Q3 earnings recap: Winners, losers & surprises
08 Nov 2023
17m
Follow this podcast in Podwise
Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.